BioMedNewsBreaks – Brain Scientific Inc.’s (BRSF) Devices Addressing COVID, Research-Related Challenges in Neurological Market

October 1, 2021 14:00:24

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, has solved issues related to offering neurological services during COVID. The new surge in the Delta variant highlights two problems in hospitals and the neurological market: staff shortages and contamination. “When it comes to neurological services during COVID, Brain Scientific has solved these issues with its two FDA-cleared EEG technologies — the NeuroCap and NeuroEEG. Easy to administer and disposable (the NeuroCap), these low-cost devices allow staff to provide EEGs at the patient’s bedside,” reads a recent article. Brain Scientific’s NeuroCap is disposable, and both devices take five minutes to set up rather than the 30 to 45 minutes it takes to fit a traditional EEG, thus reducing contamination risk. Researchers can also administer the devices because it is not necessary to have medical training to fit the cap. “Data can be collected for more extended periods as the device is portable and worn for up to four hours. The process is also much simpler for the test subject.”

To view the full article, visit https://ibn.fm/c7FkU

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork